ICML 2023 | Fixed-duration treatment strategies for frontline and relapsed CLL
In this video, Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses the success and future potential of fixed-duration treatment strategies in frontline and relapsed chronic lymphocytic leukemia (CLL). Dr Al-Sawaf highlights studies of fixed-duration venetoclax plus obinutuzumab or ibrutinib for frontline CLL, and of venetoclax plus rituximab in relapsed CLL, where sustained efficacy has been observed. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The fixed-duration treatments are really here to stay in CLL. So definitely with the data that we have in the frontline with venetoclax-obinutuzumab, with the updated data that we are seeing on venetoclax in combination with ibrutinib as fixed-duration, again for roughly a year, we again see sustained efficacy in these long-term observations. And then in parallel we are seeing also data on fixed-duration strategies in the relapsed/refractory setting with venetoclax-rituximab as established in the MURANO study...
The fixed-duration treatments are really here to stay in CLL. So definitely with the data that we have in the frontline with venetoclax-obinutuzumab, with the updated data that we are seeing on venetoclax in combination with ibrutinib as fixed-duration, again for roughly a year, we again see sustained efficacy in these long-term observations. And then in parallel we are seeing also data on fixed-duration strategies in the relapsed/refractory setting with venetoclax-rituximab as established in the MURANO study. And here again we see sustained efficacy in patients that are off treatment and are able to maintain their remission for several years. So in that sense, we are clearly seeing that the fixed-duration strategy with targeted agents by a sensible combination of different compounds is a very effective and feasible way to manage CLL.
Read more...
